Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Enlivex Announces a new publication "Apoptotic cell therapy for cytokine storm associated with acute severe sepsis" in Cell Death & Disease, a Nature Research Journal

- Data show a 90% decrease in mortality with Allocetra treatment in a murine cecal ligation and puncture severe sepsis model

ENLV : 5.50 (+3.19%)
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRA, the...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday,...

ENLV : 5.50 (+3.19%)
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting

- Exploratory endpoint analyses demonstrated Allocetra's potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies

ENLV : 5.50 (+3.19%)
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of Allocetra (formerly referred to...

ENLV : 5.50 (+3.19%)
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) selected the Company's planned COVID-19 and sepsis clinical...

ENLV : 5.50 (+3.19%)
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

- Final Analysis Comparing 10 Allocetra-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile...

ENLV : 5.50 (+3.19%)
Israel Patent Office Grants New Patent Covering Enlivex's Allocetra Immunotherapy Treatment

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ALLOCETRA, the company's immunotherapy candidate....

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea

Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain institutional investors of...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity of Allocetra, following the first confirmed...

ENLV : 5.50 (+3.19%)
Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a scientific presentation of two posters: (i) Allocetra-OTS: Early Apoptotic...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares

Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ: ENLV) today announced that it has withdrawn its previously announced proposed underwritten public offering of ordinary shares due to market...

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares

Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ:

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today reported completion of patient recruitment into the Company's Phase Ib clinical trial in patients with severe sepsis....

ENLV : 5.50 (+3.19%)
Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies...

ENLV : 5.50 (+3.19%)
Company News For Nov 5, 2019

Companies In The News Are: WMGI, ENLV, CRNT, UAA

WMGI : 30.25 (+0.36%)
UAA : 9.82 (+1.55%)
CRNT : 2.80 (+1.82%)
ENLV : 5.50 (+3.19%)

Van Meerten Stock Picks

Ebay - Pick of the Day
Today Ebay (EBAY) is a Volume Leader on Barchart: 100% technical buy signals Trend Spotter buy signal Above its 20, 50 and 100 Day moving averages 16 new highs and up 26.
EBAY -0.42
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar